There is a newer version
of
this Section
2021 Georgia Code
Title 31 - Health
Chapter 52 - Terminally Ill Patient's Right to Try Investigational Drugs, Biological Products, and Devices
§ 31-52-3. Definitions
Universal Citation: GA Code § 31-52-3 (2021)
As used in this chapter, the term:
- "Eligible patient" means a person who meets the requirements of Code Section 31-52-4.
- "Investigational drug, biological product, or device" means a drug, biological product, or device which has successfully completed Phase I of a federal Food and Drug Administration approved clinical trial but has not yet been approved for general use by the federal Food and Drug Administration and currently remains under investigation in a federal Food and Drug Administration approved clinical trial.
- "Physician" means a person licensed to practice medicine pursuant to Article 2 of Chapter 34 of Title 43.
- "Terminal illness" means a disease that, without life-sustaining procedures, will result in death in the near future and is not considered by a treating physician to be reversible even with administration of current federal Food and Drug Administration approved and available treatments.
- "Written informed consent" means a written document that:
- Is signed by the patient; parent, if the patient is a minor; legal guardian; or health care agent designated by the patient in an advance directive for health care executed pursuant to Chapter 32 of Title 31;
- Is attested to by the patient's physician and a witness; and
- Meets the requirements of Code Section 31-52-5.
(Code 1981, §31-52-3, enacted by Ga. L. 2016, p. 345, § 1/HB 34.)
Disclaimer: These codes may not be the most recent version. Georgia may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
